Nuvation Bio, Inc. (NUVB)
4.77
+0.29
(+6.47%)
USD |
NYSE |
Oct 20, 16:00
4.91
+0.14
(+2.94%)
Pre-Market: 07:38
Nuvation Bio Research and Development Expense (TTM) : 128.85M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 128.85M |
| March 31, 2026 | 125.55M |
| December 31, 2025 | 115.11M |
| September 30, 2025 | 110.11M |
| June 30, 2025 | 108.99M |
| March 31, 2025 | 110.88M |
| December 31, 2024 | 99.12M |
| September 30, 2024 | 85.17M |
| June 30, 2024 | 76.00M |
| March 31, 2024 | 65.34M |
| December 31, 2023 | 71.29M |
| September 30, 2023 | 72.81M |
| Date | Value |
|---|---|
| June 30, 2023 | 75.54M |
| March 31, 2023 | 85.87M |
| December 31, 2022 | 87.82M |
| September 30, 2022 | 92.95M |
| June 30, 2022 | 88.78M |
| March 31, 2022 | 73.89M |
| December 31, 2021 | 69.04M |
| September 30, 2021 | 56.37M |
| June 30, 2021 | 47.88M |
| March 31, 2021 | 41.19M |
| December 31, 2020 | 32.60M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Bristol Myers Squibb Co. | 9.548B |
| Johnson & Johnson | 16.02B |
| Pfizer Inc. | 10.82B |
| Eli Lilly & Co. | 14.60B |
| Merck & Co., Inc. | 27.26B |